share_log

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24

Truist Securities維持對Catalyst Pharmicals的買入評級
Benzinga ·  2023/06/21 12:56

Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $22 to $24.

Truist Securities分析師Joon Lee維持Catalyst Pharmicals(納斯達克股票代碼:CPRX)的買入,並將目標股價從22美元上調至24美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論